GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$53.09
-0.57 (-1.06%)
▼
5d:
+1.12%
30d:
+6.78%
90d:
-6.35%
HOLD
MODERATE Confidence
Analysis Updated: Jul 6, 2026 12:00 AM ET
Earnings: Jul 28, 2026
20d
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GSK shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GSK shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$70.48
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$43.76
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $53.09, which is considered extended relative to its 30-day fair value range of $50.40 to $52.71. The stock's valuation (Forward PE: 10.4) is in line with its historical norms (10.5). Remarkably, the market is currently pricing in an annual earnings decline of 0.4% over the next few years. This pessimistic expectation contrasts with the company's recent 8.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GSK is in a strong downtrend. The price is approaching resistance at $53.84. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GSK has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GSK is in a strong downtrend. The price is approaching resistance at $53.84. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GSK has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$50.40 -
$52.71
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($56.63)
Trading Range Analysis
30-Day Trading Range
$50.40 -
$52.71
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$50.59
Resistance Level
$53.84
Current Trend
Strong Downtrend
Technical data as of
Jul 6, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.36
Wall Street Target
$56.63
(+6.7%)
Revenue Growth (YoY)
1.5%
Earnings Growth (YoY)
8.4%
Profit Margin
17.8%
Valuation Discount vs History
-0.4% cheaper
PE vs Historical
10.4 vs 10.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.4%
(market-implied from PE analysis)
1-Year Target
$52.88
(0%)
2-Year Target
$52.67
(-1%)
3-Year Target
$52.46
(-1%)
3-Yr Target (if PE normalizes)
(PE: 10→11)
$53.17
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 7.1%)
$137.16
(+158%)
Base:
(SPY PE: 10.4, Growth: 7.1%)
$65.24
(+23%)
Bear:
(PE: 8.8, Growth: 7.1%)
$55.45
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 14.31 | Current EPS (TTM): $3.75
Bull Case
$80.67
(+52%)
Analyst growth 36.7%, PE expands to 15.7
Base Case
$73.34
(+38%)
Market implied 36.7%, PE stable at 14.3
Bear Case
$36.49
(-31%)
Severe decline -20.0%, PE contracts to 12.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.4 to 10.5
Stabilization Target:
$53.81
(+1.4%)
PE Expansion Potential:
+1.4%
Share & Embed Analysis
Last updated: July 06, 2026 8:46 PM ET
Data refreshes hourly during market hours. Next update: 9:46 PM
Data refreshes hourly during market hours. Next update: 9:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1220 | 60 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 67 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$355 | 69 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 65 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$256 | 59 HOLD |
